Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight

This phase 3, double blind, placebo controlled trial evaluated the efficacy and safety of once weekly mazdutide, a glucagon like peptide 1 (GLP 1) and glucagon receptor dual agonist, in Chinese adults with obesity or overweight. Participants (N=610) were randomized to receive 4 mg or 6 mg of mazdutide or placebo for 48 weeks. At week 32, the mean percentage change in body weight was 10.09% (4 mg) and 12.55% (6 mg) compared to 0.45% with placebo (P<0.001). Significant weight loss and improvements in cardiometabolic risk factors were sustained at week 48. Adverse events were primarily gastrointestinal and mild to moderate in severity. Mazdutide demonstrated clinically meaningful weight reduction and a favorable safety profile.

This phase 3, double blind, placebo controlled trial evaluated the efficacy and safety of once weekly mazdutide, a glucagon like peptide 1 (GLP 1) and glucagon receptor dual agonist, in Chinese adults with obesity or overweight. Participants (N=610) were randomized to receive 4 mg or 6 mg of mazdutide or placebo for 48 weeks. At week 32, the mean percentage change in body weight was 10.09% (4 mg) and 12.55% (6 mg) compared to 0.45% with placebo (P<0.001). Significant weight loss and improvements in cardiometabolic risk factors were sustained at week 48. Adverse events were primarily gastrointestinal and mild to moderate in severity. Mazdutide demonstrated clinically meaningful weight reduction and a favorable safety profile.